Cognition Therapeutics, Inc.
CGTXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cognition Therapeutics, Inc. focuses on Biotechnology services and products. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and. At a $68.4M market cap, Cognition Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Market Cap
$68.4M
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-3.27
EPS (TTM)
$-0.17
EPS (Fwd)
$-0.22
ROE
-83.8%
ROA
-78.2%
Cash
$34.0M
Total Debt
$589,000
Free CF
-$24.0M
52W Change
-58.4%
Annual Financials
Cash vs Debt
Where CGTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CGTX finished 31.13% below its 150-day moving average ($1.06) and 33.64% below its 200-day moving average ($1.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGTX overbought or oversold?
At the October 20, 2026 close, CGTX's RSI(14) was 16.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $34.0M in cash comfortably exceeding the $589K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$24.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -83.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Cognition Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CGTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CGTX.